Skip to main content
Clinical Trials/JPRN-UMIN000019176
JPRN-UMIN000019176
Completed
未知

A prospective Study examining The contribution to Renal anemia treatment of ferric citrate hydrate, an Ironbased Oral phosphate binder, in hemodialysis patients with hyperphosphatemia : ASTRIO Study - ASTRIO Study

Japan Tobacco Inc.0 sites90 target enrollmentOctober 1, 2015

Overview

Phase
未知
Intervention
Not specified
Conditions
Maintenance hemodialysis patients with hyperphosphatemia
Sponsor
Japan Tobacco Inc.
Enrollment
90
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 1, 2015
End Date
August 8, 2016
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Patients who have administrated of oral iron agents within 4weeks before entry. 2\) Patients with uncontrolled serum P 3\) Patients with uncontrolled serum Ca 4\) Patients with uncontrolled serum Hb 5\) Patients with uncontrolled hypertension

Outcomes

Primary Outcomes

Not specified

Similar Trials